BlackRock, Inc. 13D and 13G filings for TCR2 Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | TCR2 Therapeutics Inc. TCRR |
BlackRock Inc. BLK |
1,037,694 2.700% |
-1,364,051 (-56.79%) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
BlackRock Inc. BLK |
2,401,745 6.300% |
-201,794 (-7.75%) |
Filing |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
BlackRock Inc. BLK |
2,603,539 7.800% |
2,603,539 (New Position) |
Filing |